jball1969

@DKSportsbook 27 pts Brunson

Predict the EXACT number of points Jalen Brunson will score in Game 5 between the Knicks and Hawks ✍️ I'm gonna check back later tonight to see who was locked in 👀

@WhiteHouse @joerogan This is great ! Now we have to give final approval to DC VaX cancer treatment from Northwest Biotech $NWBO

Accelerating Medical Treatments for Serious Mental Illness🇺🇸 @JoeRogan: "For 56 years we've lived under those terrible conditions. We're free of that now. Thanks to all these people... and thanks to President Trump."

Vegas trying to get UCLA bettors to cash out. Lauren Betts will be just fine ! Let’s go UCLA!! @laurenbetts12 let’s go Lauren !

@DraftKings 274

Who wants to play a game? 🧐 Thinking of a number 1 to 1,000 👀 You better be first to guess it 🤝

@biggercapital What your current view on PULM ?

$PULM

@Kelly712717541 1.00 price target ??? I know it’s 70% upside but if he knows NWBO company it’s $5.00 as a starting point if he believes in the science and company !

$nwbo

@prtllyfnctnl @PlainCrispy @DKSportsbook What happens if someone bets hoftstra and they are in NJ ? They don’t win ?

@PlainCrispy @DKSportsbook yes

sniff… sniff… snfffff 🐶 I'm trying to sniff out a big underdog today. Give me an upset during day 2 of the tournament. I'll be checking the comments again so you'll want to be right. 👑Reminder: King of the Dogs is LIVE all weekend on the DK app. Don't miss out.

@LakeShowYo 28 points 7 rebounds 9 assists - 44 combo points . Send $77 after game. Thanks !

Giving $77 to whoever predicts Luka’s statline tonight 👀🪄 (PTS-REB-AST)

@TheFigen_ Think I am going 1D . Might be a little crowded . How long is the flight ?

Well, which seat would you choose?

@DKSportsbook Ryan Dunn

10 games across the NBA on 3/3 ‼️ Name a player that will score EXACTLY 3 points today ✍️

@DraftKings No shot ! More people left their TV on without watching the halftime show than any Super Bowl in history .

MORE PEOPLE WATCHED BAD BUNNY'S HALFTIME SHOW THAN SUPER BOWL LX ITSELF 🤯 (h/t NBC)

@DraftKings Wemby king of the court baby !!! And tomorrow $DKNG earnings will be good . Super Bowl DraftKings will be icing on cake for next earnings

WEMBY IN THE FIRST QUARTER: 👽 25 PTS in 8 MIN 👽 3-for-4 3PT 👽 8-for-9 FG 👽 6-for-8 FT 👽 3 REB 👽 1 STL 👽 1 BLK ON PACE FOR A 100 POINT GAME 🤯

Need Kyren Williams TD tonight to hit the Free Touchdown pass ! Anyone ever hit 7 out of 7 and what was payoff ??#Draftkings

@DK_Assist @WhanotA78982 Any update on Jennings winnings ?

@WhanotA78982 The team's running the numbers now and we'll have the total for you first thing in the morning!

JAUAN JENNINGS SCORES A 38-YARD TD TO TAKE THE KING OF THE END ZONE LEAD WITH 2:23 LEFT IN THE 4TH QUARTER ‼️

@schoondoggy @DKSportsbook I am talking about leaderboard during game like they do with NBA king of the court . you can see live if you are currently winning shows amount

@jball1969 @DKSportsbook Its one game, check espn for the scoring plays

Jauan Jennings is your King of the End Zone 👑

@Malone_Wealth @glen_bwrhr42 Karl Malone was the last Malone to deliver ! NWBO should be helping save lives make it happen

@glen_bwrhr42 Have her contact me.

Which public company CEO should I reach out to next to help them stop the manipulation of their stock price?

@metacollectiveG I agree ! Just puzzling why stock not going up in anticipation of MHRA . Should be much higher

$NWBO Our group of investors; not just stock geeks studying charts and normal tools for amateur retail investors We’re Physicians, Engineers, Wall Streeters, PhDs, ex Pharma, former CIA Financial analysts, Oil/Gas Execs, thinkers and doers. I wouldn’t bet against us

@alphavestcap @nwbo Hydro has been short for over 5 years

📷Slave1 @nwbo Re: HyGro post# 792142 Sunday, October 12, 2025 2:59:30 PM That is not accurate. UCLA’s dendritic-cell vaccine patents are exclusively licensed to Northwest Biotherapeutics under a worldwide agreement with the Regents of the University of California. 1.  UCLA to NWBO Exclusive License NWBO’s SEC filings state: “We hold an exclusive, worldwide license from the University of California covering dendritic-cell-based vaccines invented by Dr. Linda Liau and colleagues. The license provides us rights to develop and commercialize such vaccines for all tumor types.” (NWBO Form 10-K, March 2024, “Business – Intellectual Property”) The key patent family, “Optimally Activated Dendritic Cells That Induce an Improved or Increased Anti-Tumor Immune Response” (WO 2017/004230 to US 11,124,768 B2 to EP 4574159 A2 to IL 256522 B2 to CN 107849537 A), lists Dr. Linda Liau and Dr. Robert Prins as inventors, with Northwest Biotherapeutics as the assignee and licensee of record. The license is exclusive, worldwide, and sublicensable. UCLA retains inventorship, but NWBO holds all commercial rights. UCLA cannot independently market or license DC-Vax. NWBO controls the commercial pathway globally. 2.  NWBO’s Expanded IP through Roswell Park and the University of Pittsburgh NWBO’s June 17, 2024 press release announced: “NW Bio has obtained exclusive worldwide rights to five new patent families from Dr. Pawel Kalinski’s work at Roswell Park covering enhanced dendritic cells, chemokine-modulation regimens, and tumor-microenvironment conditioning designed to boost immune responses and overcome resistance to checkpoint inhibitors.” This follows NWBO’s 2023 license of Dr. Kalinski’s earlier University of Pittsburgh aDC1 patents, covering IL-12–dominant Type-1 polarized dendritic-cell methods. Together these portfolios give NWBO control over: I. The original UCLA DC-Vax blueprint (whole-tumor-lysate loading, maturation, and clinical validation in glioblastoma). II. The Kalinski IL-12 enhancement layer (aDC1 and CXCR3/CCR5 DC platforms that strengthen potency and trafficking). 3.  Automated Manufacturing IP (Flaskworks EDEN and EDITH) NWBO owns Flaskworks LLC and its patented EDEN and EDITH systems, which include nine granted U.S. patents and international counterparts extending through 2041. These systems automate dendritic-cell production and digitally verify every manufacturing step, satisfying both MHRA SI 87 and FDA CNPV requirements. This integration gives NWBO control over the full manufacturing and quality infrastructure behind DC-Vax. 4.  Freedom to Operate Across All Solid TumorsThe UCLA license is not limited to glioblastoma. The SEC filings explicitly state “for all tumor types,” meaning NWBO has legal freedom to expand DC-Vax-L and DC-Vax-Direct into any solid-tumor indication, including ovarian, lung, and pancreatic cancers. No other entity can commercialize the same technology without NWBO’s consent or sublicense. Conclusion The suggestion that UCLA retains independent ownership of the DC-Vax technology is incorrect. UCLA is the originating research institution, while NWBO holds the exclusive global commercial rights. NWBO has further consolidated the field by licensing complementary intellectual property from the University of Pittsburgh and Roswell Park and by acquiring Flaskworks’ automated manufacturing patents. The company now holds complete freedom to operate in dendthe bank stated that “the equity bull market and the

@andrewcaravello Let’s get this approved asap and have lives saved everyday

🧬 The Digital Gate: Why $NWBO #DCVax-L Marks the Start of Scalable Personalized Medicine TL;DR DCVax-L isn’t just a new therapy; it’s the first oncology product built for a fully digital, paperless GMP world where each patient’s batch is orchestrated by software, verified in real time, and released with continuous data integrity. The UK has now hard-wired this paradigm into law and guidance. What looks like “silence” is the MHRA completing a first-in-class validation of the system, not just the product. That’s good news: it means the tracks are being laid for scale, speed, and trust. 1) More than a product—this is a new way to make medicine DCVax-L is manufactured one patient at a time from each person’s tumor and immune cells. That makes data flow and process control the real factory. Instead of clipboards and binders, every step (collection, culture, activation, QC, release) is captured as an electronic batch record with audit trails, exception handling, and remote QA. A paperless line isn’t a tech flourish; it’s how you make a one-patient-one-batch therapy safe, repeatable, and auditable. 2) The UK quietly built the rulebook for it In 2025 the UK put a world-first framework into effect for modular and point-of-care manufacture. It codifies how personalized medicines can be prepared in small batches near the patient, with a Control Site providing central oversight, GMP licensing, and digital quality control. This isn’t theory; it’s active policy designed for automation, e-records, and real-time oversight—exactly the infrastructure DCVax-L rides on. 3) Proof the digital line works under GMP A two-year collaboration between the UK’s Cell & Gene Therapy Catapult and Autolomous converted a real gene-therapy process from paper to a GMP-compliant digital workflow. Measured results: 65% faster QA review, 40% fewer manual entries, ~894 pages of paper eliminated per batch, with near-zero transcription errors. That is the regulator-grade evidence that a software-defined line can improve quality and speed at the same time. 4) Why the CHM silence = system validation, not trouble First-in-class doesn’t just test a dossier; it tests the operating system. When the system is digital—electronic batch records, automated checks, remote QP release—validation happens behind closed doors until it’s finished. The outcome won’t merely be a product approval; it will be the first license landing on a fully digital GMP backbone for a personalized cancer vaccine. That’s a higher bar—and a stronger green light when it arrives. 5) Investor read-through: platform, moat, and momentum •Platform validation: DCVax-L becomes the reference pattern for future autologous ATMPs using digital GMP. •Moat: Advent’s paperless, audit-ready infrastructure is not trivial to replicate, creating durable advantage. •Momentum: UK law, guidance, and the Catapult’s evidence mean regulators expect digital manufacturing; the rails are now laid for speed and scale. Bottom line: this is what you want before a first-of-its-kind approval—a regulator-sanctioned, software-orchestrated manufacturing system that can carry the weight of success. Not delay. Deliverability. Sources 1.CGT Catapult & Autolomous — digital GMP case study (65% faster QA; 40% fewer manual entries; zero paper) ct.catapult.org.uk/news/cgt-catap… 2.UK Government—New regulations enabling modular/point-of-care manufacture (MHRA press release) gov.uk/government/new… 3.MHRA MedRegs blog—Decentralised Manufacturing: emerging considerations (Control Site, inspection, automation, data integrity) medregs.blog.gov.uk/2025/09/15/dec… 4.CGT Catapult—“MHRA introduces regulations that allow decentralised manufacturing of therapies” (sector interpretation and link-through to gov.uk) ct.catapult.org.uk/news/mhra-intr… 5.RAPS—“MHRA releases spate of new guidelines on decentralized manufacturing” (summary of 2025 guidance set) raps.org/news-and-artic… 6.CGT Catapult—Whitepaper landing page: “Collaboration to fast-track digital transformation for the advanced therapies industry” ct.catapult.org.uk/resources/arti… Disclaimer This narrative is for information only and is not investment advice. The sources above are official or industry webpages current as of October 2025. Always verify details directly from primary regulatory publications and company statements.